Confluence Wealth Services Inc. boosted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,419 shares of the company’s stock after buying an additional 798 shares during the quarter. Johnson & Johnson accounts for approximately 1.2% of Confluence Wealth Services Inc.’s holdings, making the stock its 18th biggest holding. Confluence Wealth Services Inc.’s holdings in Johnson & Johnson were worth $4,667,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of the stock. Glassy Mountain Advisors Inc. acquired a new stake in Johnson & Johnson during the fourth quarter worth about $35,000. Retirement Financial Solutions LLC bought a new stake in Johnson & Johnson during the fourth quarter worth approximately $40,000. TD Capital Management LLC bought a new stake in Johnson & Johnson during the third quarter worth approximately $48,000. VitalStone Financial LLC bought a new stake in Johnson & Johnson during the fourth quarter worth approximately $52,000. Finally, Iron Horse Wealth Management LLC lifted its position in shares of Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after acquiring an additional 159 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.
Insider Transactions at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.20% of the stock is owned by corporate insiders.
Johnson & Johnson Trading Down 1.4 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The company had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. During the same period in the previous year, the firm posted $2.67 earnings per share. The company’s revenue was up 5.6% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a $1.19 dividend. The ex-dividend date of this dividend is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson’s payout ratio is currently 99.58%.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on JNJ shares. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Piper Sandler lowered their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. UBS Group initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price on the stock. Finally, TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $173.00.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.